



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/644,052	08/19/2003	Arthur M. Krieg	C1037.70048US00	4791

23628 7590 09/25/2006

WOLF GREENFIELD & SACKS, PC
FEDERAL RESERVE PLAZA
600 ATLANTIC AVENUE
BOSTON, MA 02210-2206

EXAMINER

GANGLE, BRIAN J

ART UNIT PAPER NUMBER

1645

DATE MAILED: 09/25/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

10644052

EXAMINER

Nina A. Archie

ART UNIT

PAPER

1045

20060913

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

The application contains variable sequences. The applicant should disclose the whole sequence for sequence ID NOs. 296, 301, 315, 311-312.

The applicant should disclose the whole sequence for each sequence; sequence ID NOs. 311-312. The applicant cannot have X as an identifier for C, G, or phosphorothioate for sequence ID NO. 18 and claim 99. X is specific for a 3-(3-amino-3-carboxy-propyl)uridine,(acp3)u (See MPEP 2400 Table 2 List of Modified Nucleotides). Applicant should disclose longest sequence for claims 96-99 because the sequence is between 0-20 nucleotides.

The applicant should disclose the longest sequence for all sequence ID NOs. 296, 301, 315, 311-312, 18, 96, 97, 98, and 99. Applicant should also indicate in the appropriate field code what is deleted and include what residues can be absent.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nina Archie whose telephone number is (571) 272-9938.

Patricia A. Duffy
PATRICIA A. DUFFY
PRIMARY EXAMINER